These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31338879)

  • 21. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
    Mey UJM; Renner C; von Moos R
    Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 24. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.
    Parker R; Clifton-Bligh R; Molloy MP
    Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A broad expression profile of the GMR-GAL4 driver in Drosophila melanogaster.
    Li WZ; Li SL; Zheng HY; Zhang SP; Xue L
    Genet Mol Res; 2012 Aug; 11(3):1997-2002. PubMed ID: 22911584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-transcriptional silencing and functional characterization of the Drosophila melanogaster homolog of human Surf1.
    Zordan MA; Cisotto P; Benna C; Agostino A; Rizzo G; Piccin A; Pegoraro M; Sandrelli F; Perini G; Tognon G; De Caro R; Peron S; Kronniè TT; Megighian A; Reggiani C; Zeviani M; Costa R
    Genetics; 2006 Jan; 172(1):229-41. PubMed ID: 16172499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The purine synthesis gene Prat2 is required for Drosophila metamorphosis, as revealed by inverted-repeat-mediated RNA interference.
    Ji Y; Clark DV
    Genetics; 2006 Mar; 172(3):1621-31. PubMed ID: 16322507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferation of both somatic and germ cells is affected in the Drosophila mutants of raf proto-oncogene.
    Nishida Y; Hata M; Ayaki T; Ryo H; Yamagata M; Shimizu K; Nishizuka Y
    EMBO J; 1988 Mar; 7(3):775-81. PubMed ID: 3135183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cobimetinib.
    Signorelli J; Shah Gandhi A
    Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
    Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cobimetinib and vemurafenib for the treatment of melanoma.
    Boespflug A; Thomas L
    Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cobimetinib: First Global Approval.
    Garnock-Jones KP
    Drugs; 2015 Oct; 75(15):1823-30. PubMed ID: 26452567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The function of Drosophila larval class IV dendritic arborization sensory neurons in the larval-pupal transition is separable from their function in mechanical nociception responses.
    Brown HE; Desai T; Murphy AJ; Pancholi H; Schmidt ZW; Swahn H; Liebl EC
    PLoS One; 2017; 12(9):e0184950. PubMed ID: 28910410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.
    Vido MJ; Le K; Hartsough EJ; Aplin AE
    Cell Rep; 2018 Nov; 25(6):1501-1510.e3. PubMed ID: 30404005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.